In vitro release and in vivo absorption in beagle dogs of meloxicam from Eudragit® FS 30 D-coated pellets

International Journal of Pharmaceutics

Volumn 322, Issue 1-2, 2006, Pages 104-112

  Gao, Chunsheng ^a   Huang, Jian ^a   Jiao, Yan ^b   Shan, Li ^a   Liu, Yan ^a   Li, Ying ^a   Mei, Xingguo ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Beagle dogs; Coated pellets; Colon delivery; Eudragit FS 30 D; Meloxicam

Indexed keywords

ACRYLIC ACID METHYL ESTER; AEROSIL; BETA CYCLODEXTRIN; BUDENOFALK; BUDESONIDE; EUDRAGIT; EUDRAGIT FS 30 D; EUDRAGIT L100; EUDRAGIT L100 55; EUDRAGIT S100; HYDROXYPROPYLMETHYLCELLULOSE; MACROGOL 400; MELOXICAM; MESALAZINE; MESREN; METHACRYLIC ACID; METHACRYLIC ACID METHYL ESTER; PENTAGASTRIN; POCOL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COATING; DRUG PELLET; DRUG RELEASE; DRUG SOLUBILITY; ENTERIC COATED TABLET; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DELAYED-ACTION PREPARATIONS; DOGS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; MALE; METHYLCELLULOSE; POLYMETHACRYLIC ACIDS; SOLUBILITY; THIAZINES; THIAZOLES;

EID: 33748296312     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.05.035     Document Type: Article

References (44)

1. Akhgari A., Garekani H.A., Sadeghi F., and Azimaie M. Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery. Int. J. Pharm. 305 (2005) 22-30
2. Akimoto M., Nagahata N., Furuya A., Fukushima K., Higuchi S., and Suwa T. Gastric pH profiles of beagle dogs and their use as an alternative to human testing. Eur. J. Pharm. Biopharm. 49 (2000) 99-102
3. Aoyagi N., Ogata H., Kaniwa N., Koibuchi M., Shibazaki T., Ejima A., Tamaki N., Kamimura H., Katougi Y., and Omi Y. Bioavailability of griseofulvin from tablets in beagle dogs and correlation with dissolution rate and bioavailability in humans. J. Pharm. Sci. 71 (1982) 1169-1172
4. Basit A.W. Advances in colonic drug delivery. Drugs 65 (2005) 1991-2007
5. Bott C., Rudolph M.W., Schneider A.R., Schirrmacher S., Skalsky B., Petereit H.U., Langguth P., Dressman J.B., and Stein J. In vivo evaluation of a novel pH and time-based multiunit colonic drug delivery system. Aliment. Pharmacol. Therap. 20 (2004) 347-353
6. Bresalier R.S. Primary chemoprevention of familial adenomatous polyposis with sulindac: more questions than answers. Gastroenterology 123 (2002) 379-381
7. Brosens L.A., Iacobuzio-Donahue C.A., Keller J.J., Hustinx S.R., Carvalho R., Morsink F.H., Hylind L.M., Offerhaus G.J., Giardiello F.M., and Goggins M. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G → C COX-2 polymorphism. Clin. Cancer Res. 11 (2005) 4090-4096
8. Brown W.A., Skinner S.A., Malcontenti-Wilson C., Vogiagis D., and O'Brien P.E. Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase-1 or cyclooxygenase-2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation. Gut 48 (2001) 660-666
9. Busch U., Schmid J., Heinzel G., Schmaus H., Baierl J., Huber C., and Roth W. Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab. Dispos. 26 (1998) 576-584
10. Chourasia M.K., and Jain S.K. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci. 6 (2003) 33-66
11. Cole E.T., Scott R.A., Alyson L., and Connor A.L. Enteric coated HPMC capsules designed to achieve intestinal targeting. Int. J. Pharm. 231 (2002) 83-95
12. Dobbie Z., Muller P.Y., Heinimann K., Albrecht C., D'Orazio D., Bendik I., Muller H., and Bauerfeind P. Expression of COX-2 and Wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam. Anticancer Res. 22 (2002) 2215-2220
13. Evans D.F., Pye G., Bramley R., Clark A.G., Dyson T.J., and Hardcastle J.D. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 29 (1988) 1035-1041
14. Fadda H.M., and Basit A.W. Dissolution of pH-responsive formulations in media resembling intestinal fluids: bicarbonate versus phosphate buffers. J. Drug Deliv. Sci. Technol. 15 (2005) 273-279
15. Fazio L., Cotterchio M., Manno M., McLaughlin J., and Gallinger S. Association between colonic screening, subject characteristics, and stage of colorectal cancer. Am. J. Gastroenterol. 100 (2005) 2531-2539
16. Ghorab M.M., Abdel-Salam H.M., El-Sayad M.A., and Mekhel M.M. Tablet formulation containing meloxicam and β-cyclodextrin: mechanical characterization and bioavailability evaluation. AAPS Pharm. Sci. Tech. 5 (2004) 1-6
17. Goldman A.P., Williams C.S., Sheng H., Lamps L.W., Williams V.P., Pairet M., Morrow J.D., and DuBois R.N. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 19 (1998) 2195-2199
18. Gupta V.K., Beckert T.E., and Price J.C. A novel pH and time-based multiunit potential colonic drug delivery system. I. Development. Int. J. Pharm. 213 (2001) 83-91
19. Hu Z., Shimokawa T., Ohno T., Kimura G., Mawatari S., Kamitsuna M., Yoshikawa Y., Masuda S., and Takada K. Characterization of norfloxacine release from tablet coated with a new pH-sensitive polymer P-4135F. J. Drug Target. 7 (1999) 223-232
20. Hu Z., Mawatari S., Shimokawa T., Kimura G., Yoshikawa Y., Shibata N., and Takada K. Colon delivery efficiencies of intestinal pressure-controlled colon delivery capsules prepared by a coating machine in human subjects. J. Pharm. Pharmacol. 52 (2000) 1187-1193
21. Hussey H.J., and Tisdale M.J. Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model. Int. J. Cancer 87 (2000) 95-100
22. Huyghebaert N., Vermeire A., and Remon J.P. Alternative method for enteric coating of HPMC capsules resulting in ready-to-use enteric-coated capsules. Eur. J. Pharm. Sci. 21 (2004) 617-623
23. Huyghebaert N., Vermeire A., and Remon J.P. In vitro evaluation of coating polymers for enteric coating and human ileal targeting. Int. J. Pharm. 298 (2005) 26-37
24. Ibekwe V.C., Basit A.W., and Parsons G.E. A scintigraphic study to assess the performance of pH-responsive colonic drug delivery dosage forms in humans. AAPS Pharm. Sci. 5 (2003) W4126 (abstract)
25. Ibekwe V.C., Fadda H.M., Parsons G.E., and Basit A.W. A comparative in vitro assessment of the drug release performance of pH-responsive polymers for ileo-colonic delivery. Int. J. Pharm. 308 (2006) 52-60
26. Iruin A., Fernandez-Arevalo M., Alvarez-Fuentes J., Fini A., and Holgado M.A. Elaboration and "in vitro" characterization of 5-ASA beads. Drug Develop. Ind. Pharm. 31 (2005) 231-239
27. Ishibashi T., Ikegami K., Kubo H., Kobayashi M., Mizobe M., and Yoshino H. Evaluation of colonic absorbability of drugs in dogs using a novel colon-targeted delivery capsule (CTDC). J. Control. Release 59 (1999) 361-376
28. Khan I., Al-Awadi F.M., Thomas N., Haridas S., and Anim J.T. Cyclooxygenase-2 inhibition and experimental colitis: beneficial effects of phosphorothioated antisense oligonucleotide and meloxicam. Scand. J. Gastroenterol. 37 (2002) 1428-1436
29. Lin J.H. Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. 23 (1995) 1008-1021
30. Lui C.Y., Amidon G.L., Berardi R.R., Fleisher D., Youngberg C., and Dressman J.B. Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J. Pharm. Sci. 75 (1986) 271-274
31. Naidu N.B., Chowdary K.P.R., Murthy K.V.R., Satyanarayana V., Haymanc A.R., and Becket G. Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems. J. Pharm. Biomed. Anal. 35 (2004) 75-86
32. Niwa K., Takay T., and Morimoto T. Preparation and evaluation of a time-controlled release capsule made of ethylcellulose for colon delivery of drugs. J. Drug Target. 3 (1995) 83-89
33. Ozturk S.S., Palsson B., Donohoe B., and Dressman J. Kinetics of release from enteric-coated tablets. Pharmacol. Res. 5 (1988) 550-565
34. Quigley J.M., and Lloyd D.G. A topological study of prodrugs of 5-fluorouracil. Int. J. Pharm. 231 (2002) 241-251
35. Rudolph M.W., Klein S., Beckert T.E., Petereit H., and Dressman J.B. A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. Eur. J. Pharm. Biopharm. 51 (2001) 183-190
36. Schulze J.D., Peters E.E., Vickers A.W., Staton J.S., Coffin M.D., Parsons G.E., and Basit A.W. Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. Int. J. Pharm. 300 (2005) 67-75
37. Sinha V.R., and Kumria R. Microbially triggered drug delivery to the colon. Eur. J. Pharm. Sci. 18 (2003) 3-18
38. Stevens H.N.E., Wilson C.G., Welling P.G., Bakhshaee M., Binns J.S., Perkins A.C., Frier M., Blackshaw E.P., Frame M.W., Nichols D.J., Humphrey M.J., and Wicks S.R. Evaluation of Pulsincap™ to provide regional delivery of dofetilide to the human GI tract. Int. J. Pharm. 236 (2002) 27-34
39. Streubel A., Siepmann J., Dashevsky A., and Bodmeier R. pH-independent release of a weakly basic drug from water insoluble and soluble matrix tablets. J. Control. Release 67 (2000) 101-110
40. Taha A. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. New Engl. J. Med. 334 (1996) 1435-1439
41. Udd L., Katajisto P., Rossi D.J., Lepisto A., Lahesmaa A.M., Ylikorkala A., Jarvinen H.J., Ristimaki A.P., and Makela T.P. Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2. Gastroenterology 127 (2004) 1030-1037
42. Wilson P.J., and Basit A.W. Exploiting gastrointestinal bacteria to target drugs to the colon: an in vitro study using amylose coated tablets. Int. J. Pharm. 300 (2005) 89-94
43. Yang L., Chu J.S., and Fix J.A. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int. J. Pharm. 235 (2002) 1-15
44. Zhou R., Moench P., Heran C., Lu X., Mathias N., Faria T.N., Wall D.A., Hussain M.A., Smith R.L., and Sun D. pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model. Pharmacol. Res. 22 (2005) 188-192